Standard

The nicotinic acetylcholine receptor partial agonist varenicline and the treatment of drug dependence : a review. / Crunelle, Cleo L; Miller, Michelle L; Booij, Jan; van den Brink, Wim.

In: European Neuropsychopharmacology, Vol. 20, No. 2, 02.2010, p. 69-79.

Research output: Contribution to journalScientific review

Harvard

APA

Vancouver

Author

Crunelle, Cleo L ; Miller, Michelle L ; Booij, Jan ; van den Brink, Wim. / The nicotinic acetylcholine receptor partial agonist varenicline and the treatment of drug dependence : a review. In: European Neuropsychopharmacology. 2010 ; Vol. 20, No. 2. pp. 69-79.

BibTeX

@article{9bac4a98582d4f05bc99ac804f8f1bc6,
title = "The nicotinic acetylcholine receptor partial agonist varenicline and the treatment of drug dependence: a review",
abstract = "Drug dependence is a chronic brain disease characterized by recurrent episodes of relapse, even when the person is motivated to quit. Relapse is a major problem and new pharmacotherapies are needed to prevent relapse episodes. The nicotinic acetylcholine receptor (nAChR) plays an important role in nicotine dependence, alcohol consumption and cue-induced cocaine craving. Stimulation of the nAChR has been found to alter and modulate cell firing in brain areas important for the maintenance of drug dependence. Varenicline, an alpha4beta2 nAChR partial agonist and an alpha7 nAChR full agonist registered for the treatment of nicotine dependence, significantly reduces nicotine craving and prevents relapse. In addition, varenicline reduces alcohol consumption in rats. Based on a review of the available literature, we hypothesize a potential role for varenicline in the prevention of relapse in patients recovering from drug dependence other than nicotine dependence.",
keywords = "Alcohol Drinking/drug therapy, Animals, Behavior, Addictive/drug therapy, Benzazepines/pharmacology, Brain/drug effects, Dopamine/physiology, Drug Partial Agonism, Humans, Neurotransmitter Agents/physiology, Nicotinic Agonists/therapeutic use, Quinoxalines/pharmacology, Receptors, Nicotinic/drug effects, Secondary Prevention, Smoking Cessation, Substance-Related Disorders/drug therapy, Varenicline",
author = "Crunelle, {Cleo L} and Miller, {Michelle L} and Jan Booij and {van den Brink}, Wim",
year = "2010",
month = "2",
doi = "10.1016/j.euroneuro.2009.11.001",
language = "English",
volume = "20",
pages = "69--79",
journal = "European Neuropsychopharmacology",
issn = "0924-977X",
publisher = "Elsevier",
number = "2",

}

RIS

TY - JOUR

T1 - The nicotinic acetylcholine receptor partial agonist varenicline and the treatment of drug dependence

T2 - a review

AU - Crunelle, Cleo L

AU - Miller, Michelle L

AU - Booij, Jan

AU - van den Brink, Wim

PY - 2010/2

Y1 - 2010/2

N2 - Drug dependence is a chronic brain disease characterized by recurrent episodes of relapse, even when the person is motivated to quit. Relapse is a major problem and new pharmacotherapies are needed to prevent relapse episodes. The nicotinic acetylcholine receptor (nAChR) plays an important role in nicotine dependence, alcohol consumption and cue-induced cocaine craving. Stimulation of the nAChR has been found to alter and modulate cell firing in brain areas important for the maintenance of drug dependence. Varenicline, an alpha4beta2 nAChR partial agonist and an alpha7 nAChR full agonist registered for the treatment of nicotine dependence, significantly reduces nicotine craving and prevents relapse. In addition, varenicline reduces alcohol consumption in rats. Based on a review of the available literature, we hypothesize a potential role for varenicline in the prevention of relapse in patients recovering from drug dependence other than nicotine dependence.

AB - Drug dependence is a chronic brain disease characterized by recurrent episodes of relapse, even when the person is motivated to quit. Relapse is a major problem and new pharmacotherapies are needed to prevent relapse episodes. The nicotinic acetylcholine receptor (nAChR) plays an important role in nicotine dependence, alcohol consumption and cue-induced cocaine craving. Stimulation of the nAChR has been found to alter and modulate cell firing in brain areas important for the maintenance of drug dependence. Varenicline, an alpha4beta2 nAChR partial agonist and an alpha7 nAChR full agonist registered for the treatment of nicotine dependence, significantly reduces nicotine craving and prevents relapse. In addition, varenicline reduces alcohol consumption in rats. Based on a review of the available literature, we hypothesize a potential role for varenicline in the prevention of relapse in patients recovering from drug dependence other than nicotine dependence.

KW - Alcohol Drinking/drug therapy

KW - Animals

KW - Behavior, Addictive/drug therapy

KW - Benzazepines/pharmacology

KW - Brain/drug effects

KW - Dopamine/physiology

KW - Drug Partial Agonism

KW - Humans

KW - Neurotransmitter Agents/physiology

KW - Nicotinic Agonists/therapeutic use

KW - Quinoxalines/pharmacology

KW - Receptors, Nicotinic/drug effects

KW - Secondary Prevention

KW - Smoking Cessation

KW - Substance-Related Disorders/drug therapy

KW - Varenicline

U2 - 10.1016/j.euroneuro.2009.11.001

DO - 10.1016/j.euroneuro.2009.11.001

M3 - Scientific review

C2 - 19959340

VL - 20

SP - 69

EP - 79

JO - European Neuropsychopharmacology

JF - European Neuropsychopharmacology

SN - 0924-977X

IS - 2

ER -

ID: 49996383